Ensoma, a biotechnology company focused on transforming medicine through one-time, in vivo stem cell therapies, has announced the closing of a $53 million funding round. This investment comes from a group of leading investors who have previously backed the company, and it will be used to support several key initiatives that are central to Ensoma’s mission.
A significant portion of the funding will go toward advancing Ensoma’s Phase 1/2 clinical trial for its therapy known as EN-374, which targets X-linked chronic granulomatous disease (X-CGD). This rare genetic disorder affects the immune system, and Ensoma’s approach aims to offer a long-lasting solution through engineered stem cells that are modified directly inside the body. The funding will also help the company reach critical clinical milestones and generate data that could shape future treatment strategies.
Beyond this specific trial, Ensoma plans to use the funding to develop its broader cell therapy platform further. The company is exploring applications in immuno-oncology and sickle cell disease, two areas where traditional treatments often fail to deliver optimal results. By refining its technology and expanding its reach, Ensoma hopes to make a global impact on how these conditions are treated.
The list of investors supporting this round includes major names in healthcare and finance. Gilead, a publicly traded biopharmaceutical company, has not only invested but also appointed a representative to Ensoma’s board of directors. Other participants include 5AM Ventures, Catalio Capital Management, Cormorant Asset Management, Delos Capital, F-Prime, the Gates Foundation, Hanwha Impact Partners, Mirae Asset Financial Group, Qatar Investment Authority, RTW, Solasta Ventures, SymBiosis, and Viking Global Investors.
This funding round reinforces confidence in Ensoma’s approach to stem cell engineering and its potential to deliver transformative therapies that require only a single treatment. With strong backing and a clear roadmap, the company is positioned to push the boundaries of what’s possible in genetic and cellular medicine.
KEY QUOTE:
“The $53 million financing reflects growing interest in our platform’s potential to address serious diseases through one-time, outpatient treatments. This is a defining moment for Ensoma as we are now a clinical-stage company and recruiting participants for our Phase 1/2 trial for EN-374 to treat X-linked CGD. With a strong manufacturing foundation in place, as well, we are in a strong position to begin generating meaningful human data for our first-in-class in vivo HSC-directed therapy.”
Jim Burns, CEO of Ensoma
